Effect of immunomodulador AM3 on the exacerbations in patients with chronic bronchitis: A systematic review of controlled trials;Efecto del inmunomodulador AM3 sobre las agudizaciones en enfermos con bronquitis crónica: Una revisión sistemática de estudios controlados

Revista Clinica Espanola

Volumn 204, Issue 9, 2004, Pages 466-471

  Reyes Martin E ^a   Fernandez Almendros C ^b   Alvarez Sala J L ^c   Alvarez Mon M ^d  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b Industrial Farmaceutica Cantabria   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

AM3; Chronic obstructive pulmonary diseae (COPD); Inmunoferon; Metaanalysis

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOFERON; IMMUNOMODULATING AGENT; INMUNOFERON; PLACEBO;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; INFECTIOUS COMPLICATION; LUNG FUNCTION; REVIEW; SYSTEMATIC REVIEW;

EID: 6344270361     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13065976     Document Type: Review

References (25)

1. Sobradillo V, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, et al. Geographical variations in prevalence and under-diagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 2000;118:1278-85.
2. Sobradillo V. Epidemiología de la EPOC. En: de Lucas P, Peces-Barba G, editores. Enfermedad pulmonar obstructiva crónica. Monogr Neumomadrid 2001;1:15-27.
3. Miravitlles M. Evaluación económica de la EPOC. Arch Bronconeumol 2001;37:38-42.
4. Senior RM, Shapiro SD. Chronic obstructive pulmonary disease: epidemiology, pathophysiology and pathogenesis. En: Fishman AP, editor. Pulmonary diseases and disorders. Vol. 43. New York: McGraw-Hill Book Co, 1997; p. 659-81.
5. Senior RM, Anthonisen NR. Chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:139S-47.
6. American Thoracic Society. Chronic bronchitis, asthma and pulmonary emphysema: definitions and classification. Am Rev Respir Dis 1962; 85:762-8.
7. Miravitlles M, Murio C, Guerrero T on behalf of the DAFNE study group. Factors associated with relapse after treatment of acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:928-33.
8. Fagon JY, Chastre J, Trouillet JL, Domart Y, Dombret MC, Bornet M, et al. Characterization of distal bronchial microflora during acute exacerbations of chronic bronchitis. Use of protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990;142:1004-8.
9. Monso E, Ruíz J, Rosell A, Manterola J, Fiz J, Monera J, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20.
10. Soler N, Torres A, Ewig S, González J, Celis R, El-Ebiary M, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-505.
11. Kanner RE, Renzetti AD, Klauber MR, Smith CB, Golden CA. Variables associated with changes in spirometry in patients with obstructive lung disease. Am J Med 1979;67:44-50.
12. Snow V, Lascher S, Motturpilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001;134:595-9.
13. Álvarez F, Bouza E, García-Rodríguez JA, Mayer MA, Mensa J, Monsó E, et al. Uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva cró nica. Arch Bronconeumol 2002;38:81-9.
14. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997;112:310S-3.
15. Collet JP, Shapiro S, Ernst P, Renzi P, Ducruet A, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalisations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:1719-24.
16. Prieto A, Reyes E, Bernstein ED, Martínez B, Montserrat J, Izquierdo JL, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glyciphosphopeptical (Inmunoferon). Am J Respir Crit Care Med 2001;163:1578-83.
17. Saetta M, Baraldo S, Corbino L, Turato C, Bracioni F, Rea F, et al. CD + 8ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:711-7.
18. Cosio MG, Majo J, Cosio M. Inflammation of the airways and lung parenchyma in COPD. Role of T cells. Chest 2002;121:160S-5.
19. Villarrubia VG, Moreno Koch MC, Calvo C, González S, Álvarez-Mon M. The immunosenescent phenotype in mice and humans can be defined by alterations in the natural immunity. Reversal by immunomodulating with oral Inmunoferon®. Immunopharmacol Immunotoxicol 1997;19(1):53-74.
20. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
21. Jadad AR, McQuay HJ. Meta-analysis to evaluate analgesic interventions: a systematic qualitative review of their methodology. J Clin Epidemiol 1996;49:235-43.
22. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomised controlled trials. The CONSORT statement. JAMA 1996;276:7-9.
23. Grupo de trabajo de la ALAT. Recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC. Arch Bronconeumol 2001; 37:349-57.
24. Miravitlles M, Murio C, Guerrero T, Segú JL. Costs derived from management of acute exacerbations of chronic bronchitis and COPD. Eur Respir J 1999;14(30):115.
25. Miravitlles M, Segú JL, Guerrero T, Gisbert R, Murio C. Estudio farmacoeconómico del tratamiento antibiótico de las agudizaciones de la bronquitis crónica en atención primaria. Aten Primaria 2000;25:153-9.